Targeted Oncology Therapeutics – Leukemias


targeted therapeutics leukemia indications  TARGETED ONCOLOGY THERAPEUTICS – Leukemias

  LKM724F October 2021 • US$3,850 


 

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. Several targeted therapeutics leukemia indications, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Their approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of Leukemias and related blood cancers. This report examines two dozen targeted therapeutics leukemia indications including therapeutic drugs targeting leukemias, and their mechanisms of action.

 

Targeted therapeutics leukemia indications

 

 targeted therapeutics leukemia indications

 

 

  Click HERE to Order Online

 

Target Oncology Therapeutics: Leukemias – What You Will Learn

• What is the market share of approved Leukemia therapeutics?
• What is the global supply picture for targeted therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the Leukemia market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation Leukemia therapeutics?

 

Summary of Contents

Executive Summary

Targeted Oncology Therapeutics

Leukemias

The Recombinant Drug Ecosystem

mAbs and Targeted Oncology Therapeutics

Tyrosine Kinase Inhibitors

Biological Drug Activity by Region

Oncology mAbs  – Competitive Considerations

Historical Growth of Biologicals

Supply Chain Factors

Leukemias

Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Myelogenous Leukemia

Approved Biological Drugs for Leukemias

Monoclonal Antibodies Indicated for Leukemias

The Addressable Market

Drugs in Development – The Clinical Trial Picture

FDA-Approved Targeted Oncology Therapeutics for Leukemia